In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1636-1638

  Najafzadeh, Mohammad J ^a,b,c   Badali, Hamid ^a,b,d   Illnait Zaragozi, Maria Teresa ^e   De Hoog, G Sybren ^a,b,f   Meis, Jacques F ^g  

^a CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^f PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^g CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG SENSITIVITY; FONSECAEA; FONSECAEA MONOPHORA; FONSECAEA NUBICA; FONSECAEA PEDROSOI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASCOMYCOTA; CHROMOBLASTOMYCOSIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; PYRIMIDINES; TRIAZOLES;

EID: 77950165413     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01655-09     Document Type: Article

References (21)

1. Andrade, T. S., L. G. Castro, R. S. Nunes, V. M. Gimenes, and A. E. Cury. 2004. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 47:216-221.
2. Attapattu Maya, C. 1997. Chromoblastomycosis - a clinical and mycological study of 71 cases from Sri Lanka. Mycopathologia 137:145-151.
3. Bonifaz, A., E. Martinez-Soto, E. Carrasco-Gerard, and J. Peniche. 1997. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int. J. Dermatol. 36:542-547.
4. Bonifaz, A., E. Carrasco-Gerard, and A. Saul. 2001. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44:1-7.
5. Bonifaz, A., V. Paredes-Solis, and A. Saul. 2004. Treating chromoblastomycosis with systemic antifungals. Expert Opin. Pharmacother. 5:247-254.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. de Bedout, C., B. L. Gomez, and A. Restrepo. 1997. In vitro susceptibility testing of Fonsecaea pedrosoi to antifungals. Rev. Inst. Med. Trop. Sao Paulo 39:145-148.
8. De Hoog, G. S., D. Attili-Angelis, V. A. Vicente, A. H. Gerrits Van Den Ende, and F. Queiroz-Telles. 2004. Molecular ecology and pathogenic potential of Fonsecaea species. Med. Mycol. 42:405-416.
9. Esterre, P., and F. Queiroz-Telles. 2006. Management of chromoblastomycosis: novel perspectives. Curr. Opin. Infect. Dis. 19:148-152.
10. Garnica, M., M. Nucci, and F. Queiroz-Telles. 2009. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Curr. Opin. Infect. Dis. 22:559-563.
11. Guinea, J., and E. Bouza. 2008. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 3:603-615.
12. Najafzadeh, M. J., C. Gueidan, H. Badali, A. H. Gerrits Van Den Ende, L. Xi, and G. S. De Hoog. 2009. Genetic diversity and species delimitation in the opportunistic genus Fonsecaea. Med. Mycol. 47:17-25.
13. Najafzadeh, M. J., A. Rezusta, M. I. Cameo, M. L. Zubiri, M. C. Yus, H. Badali, M. J. Revillo, and G. S. De Hoog. 1 June 2009, posting date. Successful treatment of chromoblastomycosis of 36 years duration caused by Fonsecaea monophora. Med. Mycol. doi: 10.1080/13693780903008813.
14. Negroni, R., A. Tobon, B. Bustamante, M. A. Shikanai-Yasuda, H. Patino, and A. Restrepo. 2005. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev. Inst. Med. Trop. Sao Paulo 47:339-346.
15. Queiroz-Telles, F., K. S. Purim, J. N. Fillus, G. F. Bordignon, R. P. Lameira, J. Van Cutsem, and G. Cauwenbergh. 1992. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int. J. Dermatol. 31:805-812.
16. Queiroz-Telles, F., P. Esterre, M. Perez-Blanco, R. G. Vitale, C. G. Salgado, and A. Bonifaz. 2009. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med. Mycol. 47:3-15.
17. Silva, J. P., W. de Souza, and S. Rozental. 1999. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic region (Brazil). Mycopathologia 143:171-175.
18. Surash, S., A. Tyagi, G. S. de Hoog, J. S. Zeng, R. C. Barton, and R. P. Hobson. 2005. Cerebral phaeohyphomycosis caused by Fonsecaea monophora. Med. Mycol. 43:465-472.
19. Torres, H. A., R. Y. Hachem, R. F. Chemaly, D. P. Kontoyiannis, and I. Raad. 2005. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5:775-785.
20. Vitale, R. G., M. Perez-Blanco, and G. S. de Hoog. 2009. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med. Mycol. 47:35-40.
21. Yu, J., R. Li, M. Zhang, L. Liu, and Z. Wan. 2008. In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China. Med. Mycol. 46:745-747.